4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine has been researched along with su 6656 in 1 studies
| Studies (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Trials (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Recent Studies (post-2010) (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Studies (su 6656) | Trials (su 6656) | Recent Studies (post-2010) (su 6656) |
|---|---|---|---|---|---|
| 42 | 0 | 9 | 154 | 0 | 73 |
| Protein | Taxonomy | 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (IC50) | su 6656 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.1 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.15 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.17 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.02 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.13 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.77 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1765 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 8.7 | |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.11 | |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | 0.1 | |
| Aurora kinase B | Homo sapiens (human) | 0.019 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.85 | |
| Aurora kinase C | Homo sapiens (human) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and su 6656
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |